149 results about "Pharmaceutical Solutions" patented technology

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

To accurately perform an audit of a medicine including a plurality of tablets.SOLUTION: A medicine audit device includes: a rotary disc 401 that rotates around a predetermined axis; a camera 501 that images a medicine placed on the rotating rotary disc 401; and an imaging / audit processing part that determines a type or the number of medicines imaged by the camera 501. In this case, for example, the camera 501 continuously images a plurality of medicine groups placed on the rotating rotary disc 401, and the imaging / audit processing part determines a type or the number of individual medicines in the medicine groups.SELECTED DRAWING: Figure 3

We provide medical services that can ensure users have access to medications. [Solution] The control unit of the server terminal accepts from the user terminal a purchase request for a desired drug and online medical consultation from the drug and medical consultation menu presented on the platform site, accepts from the user terminal an online medical consultation request related to the desired drug and online medical consultation via the platform site, provides online medical consultation to the user terminal via a clinic terminal of a clinic affiliated with the operator of the platform site, calculates a fee for the clinic terminal based on the cost price of the desired drug and the price corresponding to the online medical consultation, and sends fee information related to the fee to the clinic terminal.

To provide a radionuclide complex solution of high concentration and high chemical stability which can be used as a medicine for diagnosis and / or treatment.SOLUTION: Provided is a pharmaceutical composition comprising: (a) a complex formed by: (ai) a radionuclide; and (aii) a gastrin releasing peptide receptor peptide antagonist binding moiety linked to a chelating agent; (b) at least two stabilizers against radiolysis; and (c) optionally a surfactant.SELECTED DRAWING: None

To provide an agent for modulating expression of extracellular matrix by corneal endothelial cells.SOLUTION: The present invention pertains to an agent for modulating expression of extracellular matrix by corneal endothelial cells, containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof.SELECTED DRAWING: None

This utility model discloses a wastewater treatment agent mixing device for industrial wastewater treatment, relating to the technical field of mixing devices. The device includes an assembly frame, a pharmaceutical tank, a tank lid, a stirring rod, a drive motor, a feeding pipe, and a discharging pipe. The device places a hollow cylinder between the stirring rod and the motor shaft of the drive motor, allowing an intelligent rotary nozzle connected to the hollow cylinder via an extension pipe to rotate circumferentially with the stirring rod. This uniformly feeds the pharmaceutical solution to various positions inside the pharmaceutical tank. A buffer plate reduces backsplashing of the solution, and the extension pipe, combined with an auxiliary scraper, scrapes away any precipitated pharmaceutical solution adhering to the inner wall and bottom surface of the pharmaceutical tank, achieving rapid and thorough mixing of the solution with water and other substances.

To provide a more effective medicine for treating ASD.SOLUTION: A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 1a receptor antagonist. A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 30IU receptor antagonist. A therapeutic agent for autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 1a receptor; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the pharmaceutical composition comprises an oxytocin-receptor agonist and a vasopressin 1a receptor antagonist as active ingredients; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 30IU receptor; and a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the vasopressin-receptor antagonist is SR49059. 1a.SELECTED DRAWING: None

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

To provide a therapeutic agent for PARP inhibitor-resistant cancer.SOLUTION: The present invention relates to a pharmaceutical composition for treating or preventing a solid cancer patient having resistance to a PARP inhibitor, and the pharmaceutical composition according to the present invention can effectively reduce the size of a tumor in a patient having resistance to a PARP inhibitor.SELECTED DRAWING: Figure 4

To provide a therapeutic agent enabling treatment of a malignant tumor.SOLUTION: A therapeutic agent comprising a substance that recognizes a target expressed in an erythroblast, where the therapeutic agent is administered such that, during a dosing period, a serum concentration of the substance in a subject administered with the therapeutic agent is maintained at 10% or more of a maximum value after administration.SELECTED DRAWING: None

The present disclosure relates to pharmaceutical solutions of certain anti-N3pGlu Aβ antibodies. Uses of such pharmaceutical solutions are also disclosed, including use in the treatment of Alzheimer's disease.

The utility model discloses an epoxy resin production refining kettle which comprises a kettle body, a blanking funnel is fixedly connected to the bottom end of the kettle body, a blanking port is formed in the lower end of the middle of the blanking funnel in a penetrating mode, a feeding pipe is embedded in one side of the top end of the kettle body, a motor is fixedly connected to the middle of the top end of the kettle body, and the output end of the motor is fixedly connected with a driving rod. A plurality of stirring rods are fixedly connected to the lower end of the rod wall of the driving rod, a plurality of turning rods are fixedly connected to the upper end of the rod wall of the driving rod, rotating rings are fixedly connected to the tops, close to the outer ends, of the turning rods, and a plurality of L-shaped scraping plates are fixedly connected to the bottom ends of the rotating rings; the inner side wall of the bearing is fixedly connected with the rotating ring, the lower end of the outer wall of the kettle body is fixedly connected with a mounting ring, and the lower end of the mounting ring is fixedly connected with a plurality of supporting legs, so that the inner wall of the kettle body can be scraped and cleaned, and a large amount of liquid medicine is prevented from remaining on the inner wall of the kettle body to influence next use.

To provide an agent for treating pancreatic cancer.SOLUTION: An agent for treating pancreatic cancer comprising 1-kestose as an active ingredient.SELECTED DRAWING: Figure 1

To provide a pharmaceutical solution composition and an oral mist inhaler comprising the same.SOLUTION: A pharmaceutical solution composition provided by the present invention includes a therapeutically effective amount of molnupiravir or a metabolite thereof and a solvent. An oral mist inhaler further provided by the present invention includes a soft mist inhaler and the above pharmaceutical solution composition loaded in the soft mist inhaler. The pharmaceutical solution composition of the present invention has high stability and generates a relatively small amount of impurities. The oral mist inhaler provided by the present invention allows a user to directly inhale the above pharmaceutical solution composition, so that the composition can be rapidly absorbed and the metabolic process of the drug in the body is reduced, thereby significantly improving the bioavailability of the drug. The particles formed by atomizing the composition are extremely small, and a large amount of mist is sprayed. Compared with a conventional oral administration method, the oral mist inhaler of the present invention is easy to use and can improve comfort and convenience during medicine consumption for a user.SELECTED DRAWING: Figure 4

According to the device for preparing and transferring the sterile liquid medicine, a preparation assembly is used for preparation and sterile treatment of auxiliary materials of the sterile liquid medicine, and the preparation assembly is arranged in a non-sterile environment; the first batching tank is used for preparing main raw materials of the sterile liquid medicine, is arranged in a sterile environment and is connected with the preparation assembly; the second batching tank is movably arranged in a non-sterile environment, the interior of the second batching tank is in a sterile state, and the second batching tank is connected with the first batching tank; the power source device can generate power, so that the sterile liquid medicine auxiliary materials enter the first batching tank after being subjected to configuration and sterile treatment, and carry the sterile liquid medicine main raw materials in the first batching tank to enter the second batching tank; the second mixing tank can be moved to a position close to the filling line and is in sterile butt joint with the filling line. According to the device, continuous supply of materials among different clean environments can be ensured, meanwhile, flexible matching in the sterile liquid medicine preparation process is achieved, and the sterility of the materials can be kept.

To provide a spoon for medication capable of wrapping powder medicine with semisolid food such as ice cream and providing it to a patient.SOLUTION: The spoon 1 for medication for wrapping the medicine P with the semisolid food C and providing it to the patient is provided with a spoon 2 for placing the semisolid food C and a molding processing part 7 for molding a recess Ch for charging the medicine P to the semisolid food C. The molding processing part 7 includes a pedestal 10 covering the outer periphery of the spatula 4 of the spoon 2 and forming a space S for arranging the semisolid food C on the upper surface of the spatula 4, a top cover 20 covering the upper surface of the pedestal 10, and a boring plug 30 fitted into an insertion hole 22 formed in the top cover 20.SELECTED DRAWING: Figure 1

To provide a coronavirus killing agent.SOLUTION: The present disclosure provides coronavirus killing agents. In particular, the present disclosure provides a coronavirus disinfectant comprising a chlorous acid aqueous solution. In particular, the present disclosure provides a method for killing or disinfecting coronavirus using a chlorous acid aqueous solution. The concentration of free chlorine (assuming Cl = 35.45) in a chlorous acid aqueous solution can be at least 5ppm or higher in the absence of organic matter. The content of chlorous acid in the chlorous acid aqueous solution (HClO2 = 68.46) can be at least 200ppm or more under the presence of organic matter including disinfection of hands and the like. The coronavirus may be SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), or 2019 novel coronavirus (SARS-CoV-2).SELECTED DRAWING: None

This invention relates to a pharmaceutical supply unit and a substrate processing system thereunder, as well as a pharmaceutical supply method. It discloses a technique for ensuring the reliability and stability of the process by sensing and removing impurities generated during a chemical reaction when a pharmaceutical solution is supplied through the pharmaceutical supply unit.

To provide a method and a drug for treating viral pneumonia.SOLUTION: A pharmaceutical composition comprises a therapeutically effective amount of one or more compounds selected from the group consisting of a component of plasminogen activation pathway, a compound capable of activating plasminogen, a compound mimicking the activity of plasminogen or plasmin, a compound capable of upregulating the expression of plasminogen or an activator of plasminogen, an analog of plasminogen, an analog of plasmin, an analog of tPA or uPA, and an antagonist of fibrinolysis inhibitor.SELECTED DRAWING: None

To provide a drug distribution cart that enables stored medications to be taken out by pulling out a storage unit (drawer) in a first direction and by pulling it out in a second, opposite direction.SOLUTION: Medications to be provided to a user are stored in a drug distribution cart. The drug distribution cart, which includes a storage unit (drawer), enables the stored medications to be taken out by pulling out the drawer in a first direction or in a second direction opposite to the first.SELECTED DRAWING: Figure 1

To provide an agent for the treatment of cancer, in particular, an agent which can be used in combination with boron neutron capture therapy and photodynamic therapy for the treatment of cancer.SOLUTION: The foregoing problem is solved by providing an agent for the treatment of cancer, the agent containing: a carrier that is accumulating in cancer cells; and a boron-containing compound and / or a photosensitizer covalently bonded and / or non-covalently bonded to the carrier, and the agent being used for cancer therapy in which a subject administered with the agent is irradiated with radiation.SELECTED DRAWING: Figure 21

1. Name of the product in this design: Injection Pen. 2. Purpose of this design: For use in injecting pharmaceutical solutions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. Design 1 is designated as the basic design.

To provide a new coronavirus infectious disease aftereffect therapeutic agent.SOLUTION: A new coronavirus infectious disease aftereffect therapeutic agent screening method includes: an administration step for administering a test substance to a new coronavirus infectious disease aftereffect model animal which is a non-human mammal expressing a SARS-CoV-2 S1 protein; and an evaluation step for assessing changes in symptoms related to the new coronavirus in the model animal before and after administration of the test substance.SELECTED DRAWING: None

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

1. Name of the product in this design: Intelligent Needle-Free Injector. 2. Purpose of this design: For use in injecting pharmaceutical solutions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention provides a PTP (Press-Through Packaging) package that allows medication to be pushed out of the pocket without contamination, and also allows multiple medications to be removed at once by peeling off the lid. [Solution] A PTP packaging material comprising a container material 20 and a lid material 30, wherein the container material has a storage section 40 for storing a drug 50, and the lid material is constructed by laminating a base layer 31, an adhesive layer 32, a metal layer 33, and a heat seal layer 34 in this order, the base layer being made of a resin film, and the base layer of the lid material has a notch 60 formed in the depth direction from the outer surface of the lid material within the area corresponding to the storage section, and the notch has one of the following shapes when the diameter of the storage section is D: (1) at least two straight lines with a length of 0.4 to 1.2 times D, (2) a single curve with a length of 2.1 to 3.8 times D and whose ends are not connected, or (3) a shape consisting of two or more lines with at least one end of the line not connected to another line.

The utility model relates to sewage treatment dosing technical field, and disclose a gravity flow automatic dosing device, include: jar body, top plate, top plate fixed mounting in the top of jar body. The utility model discloses through jar body, drive motor and stirring subassembly etc. Structure mutual cooperation, when using, can utilize drive motor drive stirring subassembly in the driving gear, driven gear, spindle and stirring blade collaborative operation, the polymeric ferric sulfate etc. Pharmaceutical solution in jar body is fully and comprehensively stirred, in this way, effectively solved the problem that the solute precipitated in the jar body bottom because of the slow solution adding speed, long standing time when the pharmaceutical preparation and storage, avoided the precipitation to reduce the solution concentration uniformity, influence pharmaceutical dosing accuracy, and the situation that the precipitation accumulation reduces jar body effective volume, reduces the device operating efficiency, guaranteed the consistency of solution concentration, improved the overall operation efficiency of dosing device.

This invention provides a laboratory water tank for reducing the concentration of suspended solids in pharmaceutical solutions. The tank comprises a square tank with a downward-sloping central area. Within this recessed area, from top to bottom, are arranged the following: a sedimentation separation zone for preliminary solid-liquid separation of the liquid entering the tank; a filtration and adsorption zone connected to the lower end of the sedimentation separation zone for filtering and adsorbing the pre-separated liquid; and a purified liquid discharge zone connected to the lower end of the filtration and adsorption zone and connected to an external drainage pipe. This invention integrates sedimentation separation, multi-stage filtration, and adsorption functions, effectively intercepting and removing large particles of pharmaceutical residue and fine suspended solids from waste pharmaceutical solutions, while also effectively reducing dissolved organic matter, pigments, and odors, thus achieving effective pretreatment of laboratory waste pharmaceutical solutions at the source of discharge.

The utility model relates to the technical field of sewage treatment, and discloses an intelligent dosing system which comprises a first-layer dosing area and a second-layer dosing area which are arranged in a centralized manner, a sodium acetate dosing area, a PAC dosing area and a PAM dosing area are arranged in the first-layer dosing area, and a sodium hypochlorite dosing area is arranged in the second-layer dosing area; the sodium acetate dosing area is configured to be used for preparing a sodium acetate solution, and the sodium acetate solution is used for denitrification treatment in a sewage denitrification stage; the PAC dosing area is used for preparing a PAC solution, and the PAC solution is used for clarification treatment in the sewage precipitation stage; the PAM dosing area is used for preparing a PAM solution, and the PAM solution is used for sedimentation treatment in the sewage sedimentation stage; the sodium hypochlorite dosing area is used for preparing a sodium hypochlorite solution, and the sodium hypochlorite solution is used for disinfection treatment in the sewage treatment completion stage. According to the sewage treatment device, matched medicament solutions are directionally added according to different sewage conditions, and sewage treatment is carried out.